Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/29509

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Follow this link:
The Anabolic Steroids market to go the reverse transversal way in the next decade - The Think Curiouser

Recommendation and review posted by Bethany Smith

Oct. 21, 2020 11:00 UTC

FREIENBACH, Switzerland--(BUSINESS WIRE)-- EffRxSA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland. Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi in Switzerland.

Alkindi is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical insufficiency (AI). Alkindi is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than eighteen years of age suffering from pediatric AI and the related condition congenital adrenal hyperplasia (CAH).

Alkindi is already approved and marketed in the European Union and is the first preparation of hydrocortisone specifically designed for use in children suffering from AI. On September 29th, 2020 the US Food and Drug Administration (FDA) has also approved Alkindi for AI.

EffRx has recently submitted to Swissmedic (Switzerland) a Market Authorization Application for the registration of Alkindi. Pending successful regulatory registration, this new treatment approach is expected to be available on the Swiss market by 2022. In Switzerland there are approximately 200 patients suffering from pediatric AI.

We are extremely pleased to announce this partnership with Diurnal which demonstrates EffRx capability to expand its portfolio with promising niche and orphan medicines, commented Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. We look forward to bringing this novel therapeutic approach to Switzerland. We are confident that Alkindi provides a tangible advancement for young patients suffering from AI and their carers.

Martin Whitaker, CEO of Diurnal, commented: This partnership with EffRx further validates the quality of our products and broadens the future availability of Alkindi. EffRx is well-placed to register and market our product Alkindi in Switzerland. We have made strong progress with the sales of Alkindi across Europe since its approval and subsequent launch in 2018, and we are confident this agreement will enable further growth.

Pediatric AI, including the genetic condition CAH is a condition characterised by deficiency in cortisol, an essential hormone in regulating metabolism and the response to stress. The primary symptoms of AI are chronic fatigue and patients are at risk of adrenal crisis and death if they do not have adequate cortisol replacement. AI is either primary or secondary, with primary AI resulting from diseases intrinsic to the adrenal gland and secondary AI resulting from pituitary diseases where there is a failure of stimulation of the adrenal by the pituitary of the signalling hormone ACTH (adrenocorticotropic hormone).

About EffRx Pharmaceuticals

EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.

EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.

EffRxs go-to-market competence is proven by the development, launch and lucrative expansion of Binosto in a highly competitive European market. Our lead commercialized product, Binosto for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit http://www.diurnal.co.uk

View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005435/en/

Excerpt from:
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market...

Recommendation and review posted by Bethany Smith

First, Katie Stoll sent the company a swab from her mixed-breed dog; later, a sample of tap water from her kitchen sink. Neither sample was identified as non-human by Orig3n lab employees.

Genetic counselor Katie Stoll was skeptical when she bought an at-home genetics test kit from a company called Orig3n in December 2017.

The kit was advertised to parents looking to better understand their childrens genetic profiles.

From food allergies to natural abilities for language and learning, the results help you get to know your child even better, Orig3n said of its Childhood Development genetic test kit.

Stoll purchased the test kit not to learn more about her child, but to learn more about Orig3n, a Boston-based consumer genetics company that pivoted to COVID-19 testing last spring and is now facing sanctions from the Centers for Medicare & Medicaid Services after the lab produced at least 383 false positive coronavirus test results last summer.

Stoll, working on her own, eventually submitted two samples to Orig3n for analysis. First, she sent the company a swab from her mixed-breed dog, Ginger; then later, a sample of tap water from her kitchen sink. Neither sample was identified as non-human by Orig3n lab employees.

Stoll is a board-certified genetic counselor who now works as executive director for the Genetic Support Foundation, an Olympia, Washington-based nonprofit that aims to provide independent information about genetics.

In a 2018 complaint she wrote to the Massachusetts Department of Public Health spurred by Orig3ns failure to identify the dog and tap water samples as non-human Stoll said that in ordering the kits, she as a consumer wanted to see if the company was forthright about the potential risks and limitations of the kind of genetic testing it offered. She also wanted to know if the company required a consent form, since the test was for children.

Orig3n CEO Robin Smith said last week that while the type of DNA analysis his company offers is relatively new, it provides one tool among many to help people make decisions about their lives.

The philosophy and culture here is, let's optimistically look at how you make yourself better, which is what everybody's interested in, he said. It's just another tool in that approach.

Scientists skeptical

But direct-to-consumer genetic testing continues to be viewed with skepticism in the scientific community.

Sarah Nelson is a senior research scientist at the University of Washington specializing in the ethical and social implications of genomics the study of all of an individuals genes and direct-to-consumer genetic testing. The university'sMolecular Biology and Genetics programs were ranked sixth in the world by U.S. News & World Report.

Theres a wide range in the quality and validity of direct-to-consumer genetic testing companies and the products they offer, Nelson said, but overall, the genetics community has reservations about genetic tests billed as being able to advise people about their predisposition to certain traits.

There's skepticism that we even understand the genetic basis of diseases and traits well enough to be reporting back to individuals, just the scientific credibility, she said. Maybe in 20 years we'll know enough to give people that type of information, but right now, it's premature.

Lindsay Farrer, a medical geneticist and Boston Universitys chief of biomedical genetics, said direct-to-consumer genetic testing often misleads customers because the companies use population-level data from studies about genetic links to certain traits or diseases and wrongly applies that data into risk assessments for random individuals.

Usually, the studies used by companies like Orig3n are based on very specific populations, such as older white European women, that dont always represent the range of people ordering the tests.

The information they give, even if it's of limited applicability, the accuracy of it is, at best, modest, he said. I guess my conclusion would be buyer beware.

Orig3n fails to flag samples as non-human

Stoll watched Orig3n advertise at sporting events including NFL and NHL games with concern, but it was the companys online advertisements for its Childhood Development test kits that prompted her to place an order herself.

Stoll thinks consumer genetic test kits like the ones offered by Orig3n also push important ethical boundaries, especially when it comes to children. Children cant consent to learning information about their DNA that has the potential to shape the rest of their lives, she said, even if their parents can.

Stoll said she didnt trust Orig3n with her childs DNA or her own, so instead, she swabbed the cheek of her dog, Ginger. After sending the kit containing Gingers DNA to Orig3n, she got a full report back from the company on Jan. 18, 2018 about the dogs genetic profile, which showed, among other things, that she was likely to have mild struggles with reading.

She said she gave the company a second chance. She ordered another Childhood Development kit, and sent in a sample of tap water from her kitchen sink on March 17, 2018. Again, she got a full report back from Orig3n. According to the report, the tap water would need longer to develop skills required for language learning.

Farrer laughed out loud when he learned that Orig3n had returned profiles for Stolls dog and the sample of tap water from her kitchen sink.

I can't think of a word to describe it, but it is beyond incompetence, he said. If that's the case, they are not competent to do what they're doing. If theyre getting DNA out of tap water, then thats bacterial DNA and that is clearly different from human DNA.

If they cant generate results reliably, then its worse than snake oil, Farrer said. Its downright chicanery.

A lab in transition

The companys report on Stolls sample of tap water was signed by Orig3ns then-lab director, a board certified geneticist, which deeply disturbed Stoll.

She reached out to the lab director, who told Stoll that she had resigned from the company, and that when the tap water sample was submitted, Orig3n was transitioning to a new director.

The lab director was not on-site at the laboratory when the test was performed and she had very limited visibility into the testing operations at that time, Stoll wrote in her complaint letter.

Stoll told the DPH that she was concerned about Orig3ns ethics, its technical proficiency and its professional oversight.

I hope that (the Centers for Medicare & Medicaid Services) will investigate these concerns and act as necessary in the interest of public safety, Stoll wrote in the complaint, dated Sept. 24, 2018.

In an emailed response to a similar complaint Stoll sent to the federal Food & Drug Administration, Tim Stenzel, writing on behalf of FDA Commissioner Scott Gottlieb, said the agency takes reports like hers seriously.

...We will evaluate this matter to determine what follow-up action is appropriate, Stenzel wrote. The type and extent of any follow-up is dependent upon the nature of the problem, the possible impact on the public health, and the availability of our resources.

A DPH investigation into Orig3n conducted before Stoll filed her complaint found the lab had fixed lab issues that led to the companys failure to identify dog DNA as non-human.

In April 2020, despite three previous investigations by other agencies into quality control problems in Orig3ns lab, the FDA gave the company emergency authorization to conduct coronavirus testing.

In May, the DPH recommended Orig3n as a testing option for nursing homes facing deadly outbreaks.

For Stoll, the eventual finding by regulators that problems at Orig3ns lab led to the reporting of hundreds of false positive COVID-19 tests showed a dangerous weakness in how governmental agencies are overseeing labs that test human samples, whether those tests are used for diagnostic purposes or personal betterment. False diagnostic test results can pose a danger to patients because doctors make medical decisions based on those results.

That weakness needs to be addressed so Americans can trust the results of their lab tests, especially amid a deadly pandemic, she said.

I feel discouraged, Stoll said last week. What does the system mean when you do things the right way and you file complaints to the right agencies and nothing happens, and then something horrible like this happens? It just feels terrible, really.

Jeannette Hinkle is a reporter for The MetroWest Daily News. Reach her at jhinkle@wickedlocal.com.

Read the original post:
Skepticism led woman to send dog DNA to Orig3n. Scientists question the reliability of direct-to-consumer genetic testing and analysis. -...

Recommendation and review posted by Bethany Smith

Hereditary Testing Services Market: Introduction

Hereditary testing is usually referred to as genetic testing or DNA testing. Hereditary testing is employed to spot alterations in the DNA sequence that correlate with a disease or higher risk to develop a disease. This kind of test is often used for diagnosis before any symptoms of the disease are recognizable in order to work out the personal risk for certain multifactorial diseases. Thus, the results of hereditary testing can have far-reaching effects on a person's life.

Hereditary testing can provide important information for diagnosis, treatment, and prevention of illness; however, there are limitations. For instance, a positive result from DNA testing in a healthy individual doesn't generally mean that he would develop a disease, while in some situations, a negative result doesn't guarantee that the individual won't have a particular disorder.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79639

Key Drivers, Restraints, and Opportunities of Hereditary Testing Services Market

The global hereditary testing market is estimated to expand significantly in the near future, due to a rise in incidence of hereditary disorders and cancer and a rise in awareness & acceptance of personalized medicines. For instance, hereditary testing has been widely utilized in pharmacogenomics, also referred to as drug-gene testing. Additionally, advancements in hereditary testing techniques are expected to boost the hereditary testing market during the forecast period. However, standardization concerns of hereditary testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the hereditary testing market during the forecast period. Conversely, untapped emerging markets in developing countries are expected to offer significant opportunities for market players. For instance, healthcare systems in developing countries such as Brazil, India, and China have witnessed a significant increase in investments in healthcare and infrastructure, which boosts the demand for hereditary testing in the region.

Technological advancements in hereditary testing are likely to boost the global market during the forecast period. Advances in sequencing techniques have reduced the sequencing time and cost of hereditary testing. For instance, microarrays substantially reduce the sequencing time by utilizing microchips. These microchips employ fluorescein to spot mutations within the chromosomes. Furthermore, innovations such as exome sequencing and next-generation sequencing have reduced the cost of hereditary testing. Hence, technological advancements are projected to propel the global hereditary testing market during the forecast period.

Request for Analysis of COVID-19 Impact on Hereditary Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79639

North America to expand significantly during forecast period

North America is projected to dominate the global hereditary testing services market during the forecast period. Increased demand for hereditary testing to understand ancestry, a rise in the demand for in-vitro fertilization (IVF), and pre-implantation testing are key factors augmenting the share held by the region. Technological advancements, presence of key players, launch of new products, the demand of diagnostics for cancer detection, and rise in prevalence and incidences of autoimmune, infectious diseases in the region are major factors driving the market in the region.

The hereditary testing services market in Asia Pacific is anticipated to expand at a notable growth rate during the forecast period. Increase in patient burden suffering from chronic diseases and recent mergers & acquisitions among key players offering hereditary testing and services are estimated to propel the market in the Asia Pacific region during forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79639

Top Companies in Hereditary Testing Services Market

The global hereditary testing services market is consolidated in terms of the number of players. Key players in the global hereditary testing services market include

Pre book Hereditary Testing Services Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79639&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Excerpt from:
Hereditary Testing Services Market: Advancements in hereditary testing techniques are expected to boost the market - BioSpace

Recommendation and review posted by Bethany Smith

Global Predictive Genetic Testing & Consumer/Wellness Genomics Market: Snapshot

The use of genetic test, as pre-symptomatic testing of diseases, has gained popularity in predicting future risks by providing information on an individuals chromosomes and genetic mutations. Predictive genetic testing is relatively new but rapidly emerging arena in public health practices, especially in developed nations. It is increasingly being used to guide nutritional strategies and training outcomes for a number of disorders. Common disorders include Huntingtons disease, cystic fibrosis, phenylketonuria, Downs syndrome, breast cancer, and sickle cell anemia.

Usually conducted in healthy persons, it involves identifying certain genetic traits that may cause disease in later years of life. Some of the most common types of predictive genetic testing can be genetic susceptibility testing, predictive diagnostic, and population screening. They may be useful in persons who have family history of some treatable genetic disorders. Consumer genomics usually involves the application of whole genome sequencing essentially to classify individuals in various risk types for a variety of diseases.

While wellness genomics is used to assist persons to take appropriate health decisions that promotes their wellness and help in maintenance of better health. It typically includes various genotypic and clinical information. Coupled with preventive medicines, wellness and consumer genomics form a key role in guiding health and wellness decisions in various populations.

The offerings of predictive genetic testing and consumer/wellness genomics market is expected to play a seminal role in the ultimate discovery of personalized therapies and medicines. World over, several direct-to-consumer (DTC) genetic testing and healthcare providers offer genetic testing products and services that are not essentially focused on disease risk but offer information that are being used by individuals, to offer information, with different levels of scientific validity, to guide their decision in fitness, diet, and athletic ability.

The type of genetic testing which is employed to diagnose or predict the gene mutation or genetic changes linked to a disease is called predictive genetic testing. It is usually used in a symptomatic person to check future risks. The branch of genomics concerned with the sequencing and interpretation of the individual is called consumer genomics, while the one which predicts the genetic factors contributing to healthy living is called wellness genomics. This type of testing enables a person to make good lifestyle changes and choices.

Request For Covid19 Impact Analysis Across Industries And Markets @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=24473

The rising health care awareness and shifting population preference toward a healthy lifestyle have led to the expansion of the market for predictive genetics testing & consumer/wellness genomics. Factors such as the rising attention of the government and other private regulatory bodies toward public health care, increased effectiveness & quality of genetic testing, prevalence of chronic diseases & genetic diseases such as Parkinsons & cystic fibrosis are expected to drive the global predictive genetics testing & consumer genomics market during the forecast period. Furthermore, the rising need to understand ones family history is propelling the global market as well. However, stringent regulatory rules and ethics for the approval of genetic testing could limit the markets development through 2025.

In terms of test type, the global predictive genetics testing & consumer/wellness genomics market can be categorized into the predictive testing, consumer genomics, and wellness genomics segments. Predictive testing can be further divided into the genetic susceptibility testing, predictive diagnostic, and population screening sub-segments. On the basis of application, the global market can be split into the following groups: cancer screening, cardiovascular screening, musculoskeletal screening, diabetic screening, Parkinsons / Alzheimer disease screening, and others.

Read more here:
Potential Impact of COVID-19 on Predictive Genetic Testing & Consumer/Wellness Genomics Market - The Think Curiouser

Recommendation and review posted by Bethany Smith

Final Report will add the analysis of the impact of COVID-19 on this industry.

The report provides the forecast of the Genetic Testing Services Market for the next four years which assist Genetic Testing Services industry analyst for building and developing business strategies. The Genetic Testing Services market report contains industry top manufacturers discussion based on the companys profiles, financial analysis, overview, market revenue, and opportunities by top geographical regions.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/14325515

The Genetic Testing Services Market Report is an in-depth assessment of current state of industry and estimates forecast based on actual facts and figures. The Genetic Testing Services Market report provides analysis based on segmentations, market potential, influential trends, and the challenges that the market is facing during this COIVD- 19 pandemic. The data (tables, figures, statistics, numbers) about the Genetic Testing Services market are taken from trustworthy sources such as websites, yearly reports of the enterprises, journals, and others and were tested and validated by the expert`s.

To Understand How COVID-19 Impact is Covered in this Report Click Here

This research consists of market segmentation by Types, Application and Genetic Testing Services market division based on geographical locations. Report also segmented by top vendors provides data about company introduction, product specification and major types analysis, production market performance, sales market performance and contact information:

By Market Players:Laboratory Corporation of America Holdings, CENTOGENE AG, Illumina, Inc., F. Hoffmann-La Roche Ltd, Ambry Genetics, Eurofins Scientific, NeoGenomics Laboratories, Inc., Genomic Health, Inc., Quest Diagnostics Incorporated, 23andMe, Inc.

By Test TypePrenatal Testing, Newborn Screening, Predictive & Presymptomatic Testing, Pharmacogenomic Testing, Others

By Service ProviderHospital-based Laboratories, Diagnostic laboratories, Specialty Clinics, Others,

By ApplicationOncology, Infectious Diseases, Autoimmune Diseases, Others,

Regional Analysis Covers: USA, Europe, China, India, Southeast Asia, Japan, South America, South Africa, Others.

The Genetic Testing Services market research report is a resource, which provides current as well as upcoming technical and financial details of the industry. The detailed study in this report enables CEOs, traders, investors, and dealers to realize the market in a better way and based on that data make knowledgeable decisions.

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/14325515

Points Covered in the Genetic Testing Services Market Report:

Who are Key Manufacturers: Major market players that are concerned within the market like manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

Data regarding Key Companies: Genetic Testing Services Capability, production, price, revenue, cost, gross, profit margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and also the technological developments.

Segmentation Analysis: Genetic Testing Services Information and data by manufacturer, by region, by type, by application and etc. The report contains the SWOT analysis of the market.

Important Questions Answered in Genetic Testing Services Market Report:

Purchase This Report (Price 3500 USD for single user license) https://www.industryresearch.co/purchase/14325515

In short TOC of 2019-2024 Global and Regional Genetic Testing Services Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report

-Genetic Testing Services overview includes Brief Introduction by Major Type, Application, Region

-Production analysis includes Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

-Genetic Testing Services Sales analysis contains Global Sales Volume, Sales Price and Sales Revenue Analysis

-Consumption of Genetic Testing Services Market Analysis by Regional Market Performance and Market Share

-Genetic Testing Services Regional Market Performance and Market Share

-New Project Investment Feasibility Analysis contains SWOT Analysis

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Industry Research Co.

Phone: +14242530807/+44203239 8187

Our Other Reports:

Wheat Germ Oil for Cosmetic Market Size Report 2020: Industry by Marketing Channel, Products Sales, Revenue, Price and Gross Margin

Analgesic Creams Market Outlook to 2026 Emerging Trends and Will Generate New Growth Opportunities Status

Unplasticized Polyvinyl Chloride (uPVC) Market Size 2026: Trends and Growth, Segmentation and Key Companies with Impact of COVID-19 on Industry

Global Plant-Based Food Flavour Enhancers Market Size 2026 In-Depth Analysis of the Segmentation Which Comprises Product Type and Applications

Stem Cell Market Size 2020 Report Contains Top Manufacturer Share, Business Revenue and Industry Overview till 2025

Storage Software Market Size 2020 Report Contains Top Manufacturer Share, Business Revenue and Industry Overview till 2025

Swim Fins Market 2020 Status and SWOT Analysis by Industry Size, Share, Regions, Production, Growth Rate and Price Analysis by Type

Global Polyethylene Coated Paperboard for Packaging Market 2020 Outlook to 2026 Top Companies in Market, Trends & Growth Factors and Details for Business Development

Anti-Obesity Drugs Market Size and Share 2020 to 2025 Market Segmentationby Product Type Level, Industry Level, Analysis of COVID-19 Impact

End User Computing (EUC) Market Size and Share 2020 to 2025 Market Segmentationby Product Type Level, Industry Level, Analysis of COVID-19 Impact

Global Man Portable Military Electronics Market 2020 Segmentation and Analysis by Recent Trends, Development and Growth by Trending Regions by 2026

Read this article:
Genetic Testing Services Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 - PRnews...

Recommendation and review posted by Bethany Smith

The research analysis of Predictive Genetic Testing And Consumer (Wellness) Genomics market offers significant information regarding the major trends that define this business landscape with regards to the regional outlook and competitive scenario. The report also highlights the limitations & challenges that could hamper the industry remuneration alongside the key opportunities that will aid in business expansion. Moreover, the document provides crucial insights regarding the effect of COVID-19 pandemic on the overall market outlook.

Primary pointers from COVID-19 impact study:

Summarizing the regional landscape:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/229556

Additional details mentioned in the Predictive Genetic Testing And Consumer (Wellness) Genomics market report:

Reasons to access this Report:

The key questions answered in this report:

Significant Point Mentioned in theResearch report:

Table of Contents for market shares by application, research objectives, market sections by type and forecast years considered:

Predictive Genetic Testing And Consumer (Wellness) Genomics Market Share by Key Players: Here, capital, revenue, and price analysis by the business are included along with other sections such as development plans, areas served, products offered by key players, alliance and acquisition and headquarters distribution.

Global Growth Trends: Industry trends, the growth rate of major producers, and production analysis are the segments included in this chapter.

Market Size by Application: This segment includes Predictive Genetic Testing And Consumer (Wellness) Genomics market consumption analysis by application.

Predictive Genetic Testing And Consumer (Wellness) Genomics market Size by Type: It includes analysis of value, product utility, market percentage, and production market share by type.

Profiles of Manufacturers: Here, commanding players of the global Predictive Genetic Testing And Consumer (Wellness) Genomics market are studied based on sales area, key products, gross margin, revenue, price, and production.

Predictive Genetic Testing And Consumer (Wellness) Genomics Market Value Chain and Sales Channel Analysis: It includes customer, distributor, market value chain, and sales channel analysis.

Market Forecast: This section is focused on production and production value forecast, key producers forecast by type, application, and regions

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/229556

See the article here:
Predictive Genetic Testing And Consumer (Wellness) Genomics Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - Express Journal

Recommendation and review posted by Bethany Smith

The latest market report published by Emergen Research, titled Global Direct-to-Consumer Genetic Testing Market, presents an accurate analysis of the estimated market size, share, revenue, and sales & distribution networks of the global Direct-to-Consumer Genetic Testing market over the forecast period. The report offers an exhaustive overview of the market, along with a precise summary of the markets leading regions. Our team of analysts has studied the existing competitive landscape of the market inside out, focusing on the leading companies and their business expansion strategies. The report ends with conclusive data offering useful insights into the market growth on both regional and global levels.

The report draws the focus of the reader on the grave impact of the ongoing COVID-19 pandemic on the Direct-to-Consumer Genetic Testing industry and its vital segments and sub-segments. It elaborates on the adverse effects of the pandemic on the global economic scenario, as well as this particular business sphere. The report takes into account the key influencing factors influencing market performance in the present COVID-19 times. The market has been substantially affected by the pandemic, and significant changes have been observed in the market dynamics and demand trends. The report examines the major financial difficulties brought about by the pandemic and offers a future COVID-19 impact assessment.

Get a free sample of the report @ https://www.emergenresearch.com/request-sample/20

Key Market Players:

23andMe, Full Genome Corporation, Color Genomics, Genesis Healthcare, Helix OpCo LLC, FamilyTreeDNA, MyHeritage, Identigene, Pathway genomics, and Living DNA

Direct-to-Consumer Genetic Testing Market Segmentation:

The report categorizes the market into different key segments based on types and applications, along with key regional segmentation. The report offers insights into the segment expected to garner traction during the forecast period, and the region expected to dominate the market in the coming years.

Test Type Outlook

Distribution Channel Outlook

Application Outlook

Key Geographies Encompassed in the Report:

Request a discount on the report @ https://www.emergenresearch.com/request-discount/20

The market intelligence study takes the reader through the key parameters of the Direct-to-Consumer Genetic Testing market, including the strengths and weaknesses of the leading players, using analytical tools like the SWOT analysis and Porters Five Forces analysis. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players. The investigative study further assesses the market on the basis of market reach and consumer base in the key geographical segments. Alongside reviewing the sales network, distribution channels, pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market, the report studies several factors affecting market growth over the forecast period, such as drivers, restraints, limitations, growth prospects, and numerous macro- and micro-economic indicators. Moreover, it extensively examines the top market players and their estimated market size and share, sales volume, production and consumption rates, expansion strategies, and competitive edge.

Additionally, the report analyzes the principal strategies implemented by the companies operating across this industry vertical, such as mergers and acquisitions, collaborations, joint ventures, product launches, and brand promotions, to strengthen their global footprint. The report aims to offer a holistic examination of the industrys relevant features to the interested readers in a bid to help them leverage future growth prospects.

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/20

Key questions addressed in the report:

Get a broad analysis of the COVID19 impact on the Direct-to-Consumer Genetic Testing market @ https://www.emergenresearch.com/industry-report/direct-to-consumer-genetic-testing-market

Thank you for reading our report. For further queries regarding the report, please get in touch with us. Our team will ensure your report is customized as per your requirements.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Our expertise umbrellas the technological environment of all major industries, and our services help you map your actions to ensure optimal yield. Our analysts utilize their market proficiency to offer actionable insights that help our clients implement profitable strategies and optimize their return on investment. Our services are wide-ranging, right from technological environment analysis to technological profiling that highlights the existing opportunities in the market you can capitalize on to stay ahead of your competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

14671 110 Avenue, Surrey, British Columbia, V3R2A9

Emergen Research | Web: https://www.emergenresearch.com

E-mail: [emailprotected]

Read the original:
Direct-to-Consumer Genetic Testing Market is anticipated to Reach USD 3.33 billion by 2027 Growing at a CAGR of 13.1% | Emergen Research - PRnews...

Recommendation and review posted by Bethany Smith

Prophecy Market Insights presented the Genetic Testing market which severs comprehensive and iterative research methodology. The company focuses on minimizing deviance in order to offer the most accurate estimations and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for calculation and authenticate of the market size and for estimating quantitative aspects of the market.

Research and consulting services of Prophecy Market Insights help businesses across the world to navigate the challenges in the Genetic Testing market with confidence. The report provides sufficient insights that drive sustainable growth.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3888

Parameters involved in the Genetic Testing market include:

Segmentation Overview:

Global Genetic Testing Market, ByType:

Global Genetic Testing Market, By Disease:

Global Genetic Testing Market, By Technology:

Genetic Testing Market Key Players:

The report provides an in-depth geographical analysis of the Genetic Testing market, covering important regions, viz, North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. It also covers key countries (regions), viz, U.S., Canada, France, Germany, U.K., Italy, Russia, India, China, Japan, South Korea, Australia, Taiwan, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Mexico, Brazil, GCC, Israel, South Africa, etc.

The competitive analysis section of the report includes prominent players of the Genetic Testing market that are broadly studied on the basis of several key factors.

Highlights of the Report

Complete access to COVID-19 Impact on the Genetic Testing market dynamics, key regions, market size, growth rate and forecast to 2029

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3888

The report responds to significant inquires while working on Global Genetic Testing Market. Some important Questions Answered in Genetic Testing Market Report are:

The report on the Genetic Testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the rest here:
Genetic Testing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - TechnoWeekly

Recommendation and review posted by Bethany Smith

News Release

Thursday, October 22, 2020

NIH-funded therapy will now be tested in humans.

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical trial for later this year.

Nanoscopes findings, reported today in Nature Gene Therapy, show that totally blind micemeaning they have no light perceptionregain significant retinal function and vision after treatment. Studies described in the report showed that treated mice were significantly faster in standardized visual tests, such as navigating mazes and detecting changes in motion.

Opsins are proteins that signal other cells as part of a cascade of signals essential to visual perception. In a normal eye, opsins are expressed by the rod and cone photoreceptors in the retina. When activated by light, the photoreceptors pulse and send a signal through other retinal neurons, the optic nerve, and on to neurons in the brain.

A variety of common eye diseases, including age-related macular degeneration and retinitis pigmentosa, damage the photoreceptors, impairing vision. But while the photoreceptors may no longer fully function, other retinal neurons, including a class of cells called bipolar cells, remain intact. The investigators identified a way for bipolar cells to take on some of the work of damaged photoreceptors.

The beauty of our strategy is its simplicity, said Samarendra Mohanty, Ph.D., Nanoscope founder and corresponding author of a report on the mouse study that appears today in Nature Gene Therapy. Bipolar cells are downstream from the photoreceptors, so when the MCO1 opsin gene is added to bipolar cells in a retina with nonfunctioning photoreceptors, light sensitivity is restored.

The strategy could overcome challenges plagued by other approaches to retinal regeneration, according to the researchers. Gene replacement therapy has thus far worked principally in rare diseases that leave photoreceptors intact, such as Luxurna for Leber congenital amaurosis. Bionic eyes, such as the Argus II retinal prosthesis, require invasive surgery and wearable hardware. Other opsin replacement therapies require the intensification of light in order to reach the threshold required for signal transduction. Intense light risks further damage to the retina. Nanoscopes therapy requires a one-time injection into the eye and no hardware. MCO1 is sensitive to ambient light, so no need exists for strong light to be shined into the eye. And therapy with MCO1 could treat a wider range of degenerative retinal diseases, since photoreceptor survival not required.

The researchers found no concerning safety issues in treated mice. Examination of blood and tissues found no signs of inflammation due to treatment and the therapy had no off-target effect only bipolar cells expressed the MCO1 opsin.

Under a best-case scenario, the therapy could help patients achieve 20/60 vision, according to the researchers; however, no one knows how the restored vision will compare to normal vision.

A clinical study in people will help us understand how signaling through bipolar cells affects vision quality; for example, how well treated eyes can pick out fast-moving objects., said Subrata Batabyal, Ph.D., lead author of the manuscript. The therapy will likely be limited for treatment of patients with severe retinal disease.

If this optogenetic approach using cells spared in degenerated retina can prove to be effective in vision restoration in humans, beyond light perception, it could offer a valuable alternative to the retinal prosthesis approach for people with late-stage retinitis pigmentosa, said PaekGyu Lee, Ph.D., NEIs program officer for the Small Business Innovation Research program.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The Small Business Innovation Research (SBIR) program is a competitive awards-based funding mechanism that supports U.S.-based small businesses engaged in research and development that has the potential for commercialization. The NEI SBIR program specifically provides funding to companies developing technologies and innovations relating to blinding eye diseases, visual disorders preservation of sight, and addressing the special health problems and requirements of individuals with impaired vision.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nations medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

DOI is 10.1038/s41434-020-00200-2

###

More here:
Scientists use gene therapy and a novel light-sensing protein to restore vision in mice - National Institutes of Health

Recommendation and review posted by Bethany Smith

Research published in Nature Gene Therapy today shows how the light-sensing protein (MCO1 opsin) can restore vision in blind mice when attached to retina bipolar cells using gene therapy.

Nanoscope LLC received a Small Business Innovation Research grant from the US National Eye Institute (part of the National Institutes of Health) to develop MC01.

The research opens up the field for gene therapy for a number of degenerative retinal diseases where photoreceptors are damaged.

Opsins are proteins that signal other cells as part of a series of signals needed for sight. In a normal eye, opsins are expressed by the rod and cone photoreceptors in the retina.

A number of common eye diseases - including age-related macular degeneration and retinitis pigmentosa - damage the photoreceptors.

But while the photoreceptors may no longer fully function, other retinal neurons, including bipolar cells, remain intact. The researchers have found a way for bipolar cells to take on some of the work of damaged photoreceptors.

Biopolar cells are downstream from photoreceptors, so when the MC01 opsin gene is added to these biopolar cells, light sensitivity can be restored.

The researchers used AAV2 assisted delivery of highly photosensitive multi-characteristic opsin (MC01) onto ON-bipolar cells of mice with retinal degradation to allow activiation by ambient light.

Researchers explored the delivery efficacy by using different doses of AAV2 carrying MCO1 (vMCO1) into targeted cells and analysed the results over the 6 months after delivery. They found that treated mice were able to perform significantly faster in standardized visual tests, such as navigating mazes and detecting changes in motion.

To date, gene replacement therapy has worked mainly in diseases that leave photoreceptors intact (such as Luxturna for Leber congenital amaurosis).

The new research means that therapy with MC01 could be investigated for a wider range of degenerative retinal diseases, without requiring photoreceptors to survive.

It could also offer a better option that other solutions: bionic eyes require invasive surgery and wearable hardware; while other opsin replacement therapies require intense light to be strong enough to create a signal (with intense light risking further retina damage).

Researchers suggest that, in a best-case scenario, the therapy could help patients achieve 20/60 vision. It is likely to be limited to patients with severe retinal disease: and further research will explore how bipolar cells can be used.

Subrata Batabyal, Ph.D., lead author of the study, said: "A clinical study in people will help us understand how signaling through bipolar cells affects vision quality; for example, how well treated eyes can pick out fast-moving objects."

Source:Batabyal, S., Gajjeraman, S., Pradhan, S.et al.Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice.Gene Therapy(October 22, 2020). https://doi.org/10.1038/s41434-020-00200-2

Go here to read the rest:
Gene therapy and light-sensing protein used to restore sight in mice - BioPharma-Reporter.com

Recommendation and review posted by Bethany Smith

SparingVision has raised 44.5 million ($52.5 million) to develop its mutation-agnostic gene therapy treatment for retinitis pigmentosa (RP). The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in the 2 million RP patients.

Gene therapies including Spark TherapeuticsLuxturna are designed to address genetic drivers that cause some patients to develop RP and suffer vision loss. However, with at least 65 distinct RP-causing mutations of three different types, the numbers of patients that can be helped with any one gene-replacement therapy are relatively small. SparingVision, in contrast, is going after the whole RP market.

Its gene therapy but its mutation agnostic. The market potential is very large, unlike most gene therapies being developed, which address very specific mutations [in the eye]. The commercial viability of those mutation-specific gene therapies is kind of questionable, Stphane Boissel, who recently took over as CEO of SparingVision, said.

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

The mutation-agnostic approach is built on an understanding of RP. The deterioration of the vision of RP patients begins with the degeneration of rod photoreceptors. That causes night blindness. Over time, cone photoreceptors start to degenerate, causing vision to deteriorate to the point that a patient is legally blind, despite most known genetic mutations only affecting the rods.

SparingVisions scientific founders identified an explanation for the loss of cones. As the number of rods falls, cones receive lower levels of the neurotrophic factors released by the photoreceptors. The loss of rods leads to lower levels of the neurotrophic factors, which in turn causes the loss of cones.

The research led to a novel gene therapy approach. Unlike treatments such as Luxturna, the gene therapy does not seek to replace a faulty or missing gene. Rather, the therapy is designed to ensure cones have access to the molecules that support their preservation. The gene therapy encodes for neutrophil factor RdCVF and an enzyme, potentially enabling it to restore aerobic glycolysis in cones and protect them from oxidative stress.

The idea is not to restore vision. The idea is to slow or stop the progression of the disease by preventing the cones from further degenerating, Boissel said.

SparingVision has raised 44.5 million to pursue that idea, bringing its total series A financing haul up to around 60 million. With GMP manufacturing almost done and IND-enabling studies underway, the money will enable SparingVision to move into a clinical trial to assess the safety of its candidate next year. Once SparingVision has safety data, it will run an efficacy trial using the series A funds.

The potential to take a mutation-agnostic RP gene therapy to clinical proof of concept has attracted a diverse group of investors. Advanced therapy VC 4BIO Capital led the round with UPMC Enterprises, the venture arm of healthcare provider and insurer UPMC. Jeito Capital, Ysios Capital, Bpifrance and Foundation Fighting Blindnessa charity that funded research into RdCVFalso participated.

The syndicate that we put together is not the typical VC syndicate. This is a well-balanced group of typical VCs but also very long-term, patient-centric investors. We have no pressure to, for example, exit. The only pressure we have is to deliver a drug to the patients, Boissel said.

Boissel has taken upthat challenge after two years at Sangamo Therapeutics, which bought the last company he led, TxCell, for 72 million. The CEO is now building out the rest of the team, with a chief technical officer set to join soon and a chief medical officer slated to arrive in the new year. The team will work to advance the lead candidate into the clinic and expand into the U.S.

Read the rest here:
SparingVision raises 44.5M to develop mutation-agnostic gene therapy - FierceBiotech

Recommendation and review posted by Bethany Smith

In anticipation of our Pfizer Gene Therapy Career Event scheduled for Wednesday, October 28, 2020, BioSpace spoke with Alison Ricci, Pfizers Senior Business HR Partner- Global Sciences, Business HR for Bioprocess Research and Development, and HR Site Lead for the companys four locations in Chapel Hill and Morrisville, North Carolina, Chesterfield, Missouri and Lake Forest, Illinois.

In late August, Pfizer announced it was investing an additional $500 million into its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This is in addition to the companys continuing investment into gene therapy research and development and other areas going on throughout the company, but specifically in its North Carolina sites in Chapel Hill and Kit Creek. The companys presence in North Carolina currently exceeds 3,600 people, with 650 in Sanford. The expanded facility is expected to add over 100 new jobs.

Ricci told BioSpace the company has been investing heavily in gene therapy and in the Raleigh-Durham Research Triangle Park area. They have three facilities in and around the area that focus specifically on gene therapy, including a research facility in Morrisville, its existing clinical manufacturing site in Chapel Hill, and a very large manufacturing site in Sanford.

And in recognition of the continued investment and commitment to gene therapy, the company acquired a 60,000-square-feet building and 16 acres in Durham, which they are renovating into a clinical manufacturing site, essentially doubling our clinical manufacturing capacity.

*Rendering of Durham location

As such, the company has numerous positions in the area currently open with many more expected as the new site comes online.

Right now, we have 30 positions that were going to be advertising for that directly support gene therapy in those three different campuses, Ricci said.

The roles they will be looking to fill include what Ricci calls a multitude of individual contributor, team lead and management roles."

"For instance, weve got our R&D and analytical scientist roles; we have manufacturing engineering roles; we have technical specialist roles; and different types of manufacturing support and technology transfer roles, Ricci said.

They also have training specialist positions because there are a variety of supporting functions that go into the magic of making gene therapy work.

Ricci seemed excited about gene therapy and the part it is playing increasingly in Pfizers core mission. Speaking of Duchenne muscular dystrophy (DMD), increasingly a target of gene therapies, she noted how exciting and important it is to be able to provide a therapy that extends quality of life, that doesnt just treat symptoms, but that potentially marks a minimization of those symptoms and the elongation of life. Thats one of the central core components of who Pfizer is. Our patients are our North Star.

She also emphasized not only the science and motivation of Pfizer as an employer, but its culture.

People typically equate large organizations with a level of bureaucracy, that results in less risk and less innovation opportunities, Ricci said. In my five years with Pfizer Ive seen the culture shift to focus on innovation, inclusion, quality and smart resourcing figuring out how to free up resources so we can focus on bold moves and exciting new therapies allowing our scientists to stretch and grow, and make a difference for the patients that count on us.

The company has also structured rewards and recognition around those types of approaches, not only for people theyre bringing into the organization, but with its current staff.

Were still maintaining our focus on a combination of productivity and doing it right the first time while encouraging innovation, taking bold moves and trying new things," Ricci said. "Because thats the best way that good science is done, and patients win in the process.

She also notes that the Pfizer Gene Therapy Career Event is a great opportunity to have direct contact not only with Pfizer hiring managers, but with colleagues who are working in those same roles theyre hiring for.

Its a unique experience in terms of really understanding who Pfizer is and what we have to offer, Ricci said.

And, of course, the company is hiring throughout its worldwide operations in support of not only its COVID-19 clinical research trials and manufacturing processes, but in the numerous other areas the company focuses on.

The expansion in Sanford, North Carolina is only a part of the companys focus on building out capacity. It has committed about $5 billion in U.S.-based capital projects over the next several years.

But the North Carolina area is expanding end-to-end capabilities in gene therapy. The Kit Creek facility focuses on small scale production, from 2L flasks up to 250L bioreactors to develop the early processes that will later be used in larger scale manufacturing. The Chapel Hill facility is where the process is optimized, and staffers work at a 250L scale while developing and implementing quality control measures that include Good Manufacturing Practice (GMP) standards. The Sanford facility is designed for high-quality, efficient supply of gene therapies at clinical- and commercial-scale.

Ricci also points to Paul Mensah, Pfizers Vice President of Bioprocess Research and Development.

He has a nice, pragmatic style and approach in terms of how he continues to foster and leverage innovation, but also the science of how everyone works together to collaborate and deliver. He instills that in the leaders on the team. Ricci said.

Were continuing to focus in terms of career development and the aspirations of each colleague. There are opportunities for colleagues at Pfizer to do anything they want within the realms of the organization." Ricci said. "You can be on the frontlines of early stage development, you can work on the late stage, you can have opportunities for clinical manufacturing. You can run the gamut in terms of different roles with the scientific profile within Pfizer.

See original here:
Pfizer: Expanding North Carolina Gene Therapy Facility and Adding Jobs - BioSpace

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (Bain Capital), and RA Capital Management (RA Capital) (collectively the Investor Group) together with Sarepta Therapeutics, Inc. (Sarepta) (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced a $107 million Series A financing to create AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases. The private financing round includes a $15 million equity investment from Sarepta.

Alexander Bo Cumbo, a seasoned biopharmaceutical executive, has been appointed AavantiBios Chief Executive Officer and President, effective immediately. Mr. Cumbo joins the Company after eight years at Sarepta, where he served as Chief Commercial Officer and Executive Vice President. He will continue to serve as an advisor to Sarepta through December 31, 2020.

Headquartered in the greater Boston area, AavantiBio is co-founded by renowned gene therapy researchers Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D., who together bring thirty years of experience to the Company. AavantiBios lead program is in Friedreichs Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. AavantiBios research efforts expand on foundational research conducted by Drs. Byrne and Corti in Friedreichs Ataxia, among other rare genetic disorders. AavantiBio will benefit from strategic partnerships with the University of Floridas renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where Drs. Byrne and Corti maintain their research and clinical practices. Initial funding in AavantiBio was provided by GoFAR, an Italian patient advocacy group, and the Muscular Dystrophy Association Venture Philanthropy Fund.

The past eight years have been some of the most rewarding of my career as Sarepta has emerged as a pioneer for Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients and transformed into a genetic medicine leader, Mr. Cumbo stated. It has been a privilege to contribute to this growth and play a role in serving these communities. As I look ahead to the bright future of AavantiBio and the exciting opportunity to lead this innovative Company, this same dedication to serving unmet patient needs and to leveraging deep scientific expertise will be core to our mission. I am also thrilled to continue to collaborate with the talented team at Sarepta.

Our equity participation in AavantiBio serves our strategy to build our gene therapy engine through targeted investment in potentially life-enhancing therapies as well as partnering with renowned genetic medicine pioneers such as Drs. Byrne and Corti, stated Doug Ingram, president and CEO, Sarepta Therapeutics. Mr. Ingram continued: Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions to Sarepta. We look forward to continuing to work with Bo as he builds a strong AavantiBio team and advances therapies to treat FA and other rare diseases.

Prior to joining Sarepta in 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education at Vertex Pharmaceuticals where he built a sales force to market their first commercial drug, Incivekan oral treatment for hepatitis C. Previously, he spent nine years at Gilead Sciences where he served in multiple commercial roles supporting the companys HIV, HBV, and cardiovascular franchises. Mr. Cumbo has extensive experience building global commercial infrastructure, and throughout his career, he has contributed to the launch of 11 specialty products across multiple organizations. He received his Bachelor of Science in Laboratory Technology from Auburn University.

AavantiBio has a unique opportunity to change the lives of those living with FA and other rare diseases, Mr. Cumbo added. Central to our mission is building on the advancements in gene transfer therapies and harnessing these revolutionary technologies to realize their potential as life-altering medicines. Im excited to build a company focused on deep science, innovation, and collaboration, and grateful for the partnership with three of the biotechnology industrys most respected investors in Perceptive Advisors, Bain Capital, and RA Capital.

Our investment in AavantiBio represents a truly unique opportunity to thoughtfully advance a differentiated pipeline of innovative gene transfer therapies in areas of high unmet medical need, the Investor Group said in a statement. We are excited to collaborate with Bo Cumbo, an accomplished executive leader, and to provide the necessary resources to enable the Company to build a best-in-class gene therapy platform that brings transformative products to patients and families impacted by these devastating diseases.

The AavantiBio Board of Directors will be comprised of 8 Directors, including Mr. Cumbo, Drs. Byrne and Corti, representatives of the Investor Group, and two Independent Directors. Louise Rodino-Klapac, Ph.D., senior vice president of gene therapy for Sarepta, will serve as a Board Observer.

About Friedreichs Ataxia

Friedreichs Ataxia (also known as FA or Friedreich Ataxia) is a rare inherited genetic disease that causes movement problems and nervous system damage.Over time, the disease leads to degeneration in the spinal cord, peripheral nerves and cerebellum (the part of the brain that controls synchronization and balance) and causes impaired muscle coordination (ataxia) that gets worse over time. Poor coordination is one of the first noticeable features of FA.The neurological degeneration caused by the disease results in unsteady movements, impaired sensory function, and even the loss of speech. Affected individuals can also develop heart problems, diabetes, or curvature of the spine.However, the disorder does not affect cognitive ability. Though rare, FA affects 1 in every 40,000-50,000 people and is the most common form of hereditary ataxia in the United States.

About AavantiBio, Inc.

AavantiBios vision is to harness the transformative science of gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. Founded by distinguished gene therapy researchers out of the University of Florida, the Company is advancing a pipeline of innovative gene transfer therapies in areas of high unmet medical need, which have the potential to become the next generation of life-changing medicines. Learn more at: http://www.aavantibio.com.

AboutSarepta Therapeutics

At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

About Perceptive Advisors

Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment management firm focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. For more information visit http://www.perceptivelife.com.

About Bain Capital Life Sciences

Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally. The team focuses on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain Capital has developed global reach, deep expertise and a proven track record in life sciences industries across its Private Equity, Credit, Public Equity, Venture and Real Estate business units.

About RA Capital Management

RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation from inception through commercialization.

Sarepta Forward-Looking Statements

This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding AavantiBios plan to pursue a diversified gene therapy pipeline; the expectation that AavantiBio will maintain strong ties to the University of Florida's Powell Gene Therapy Center; AavantiBios potential to benefit from strategic partnerships with the University of Floridas Powell Gene Therapy Center and the MDA Care Center at UF Health; AavantiBios mission to build on the advancements in gene transfer therapies and harness revolutionary technologizes to realize their potential as life-altering medicines; AavantiBios potential to build a best-in-class gene therapy platform that brings transformative products to patients and families impacted by devastating diseases; and AavantiBios potential to become the next generation of life-changing medicines.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: the expected benefits and opportunities related to the investment in AavantiBio may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development; the investment in AavantiBio may not result in any viable treatments suitable for clinical research or commercialization due to a variety of reasons including the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates or may never become commercialized products due to other various reasons including any potential future inability of the parties to fulfill their commitments and obligations under the agreements, including any inability bySareptato fulfill its financial commitments to AavantiBio; even if the investment results in new commercialized products,Sareptamay not achieve any significant revenues from the sale of such products; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Companys business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

AavantiBio Contact:

Scott Lessne646-502-3569slessne@stantonprm.com

Sarepta Contacts:

For InvestorsIan Estepan617-274-4052iestepan@sarepta.com

For MediaTracy Sorrentino617-301-8566tsorrentino@sarepta.com

See the original post here:
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital...

Recommendation and review posted by Bethany Smith

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, to discuss the Companys AXO-Lenti-PD gene therapy for Parkinsons disease.

Axovants Parkinsons disease R&D Day will be moderated by Chief R&D Officer, Gavin Corcoran, M.D., and will feature presentations on the current treatment landscape and unmet medical need for people living with Parkinsons disease from the following key opinion leaders:

In addition, the Company will present data from the second cohort of the Phase 2 SUNRISE-PD trial for AXO-Lenti-PD including:

Drs. Adler, Palfi, and Eberling will be joined by Dr. Corcoran to answer questions following the formal presentations.

AXO-Lenti-PD is the only investigational gene therapy for Parkinsons disease that delivers three genes via a lentiviral vector to encode a set of critical enzymes required for endogenous dopamine synthesis, with the goal of improving motor function and restoring steady, tonic levels of dopamine in the brain. The gene therapy aims to provide patient benefit for years following a single administration.

To register for the R&D webcast, please click here.

A live audio webcast of the R&D Day can be accessed through the Events & Presentations section of the company's website at investors.axovant.com. An archived replay of the webcast will be available on the company's website following the event.

Biographies of R&D Day Panelists:

Dr. Adler has received numerous grants to investigate experimental treatments for Parkinson's disease, essential tremor, dystonia, restless legs syndrome, and chronic traumatic encephalopathy (CTE). He serves as an advisory member to many different international medical societies such as the International Parkinson and Movement Disorder Society, MDS Industry Education and Services Committee, and the American Academy of Neurology Section of Movement Disorders. Dr. Adler has a commitment to education having trained residents, 14 fellows and graduate students, and has given many invited lectures. Dr. Adlers main research interests are investigating tissue diagnostic tests for Parkinsons disease, biomarkers for an early diagnosis of Parkinsons disease and PD with dementia, and identification of new treatments for PD and PD with dementia. He also has been investigating essential tremor, restless legs syndrome, and dystonia. He has published over 400 research papers and reviews, and edited a book entitled Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. In 2006, Dr. Adler was awarded the Mayo Clinic Distinguished Investigator of the Year Award.

Dr. Palfi has published extensively on trophic factor- and enzyme-based gene therapy in Parkinsons disease and Huntingtons disease. He is a principal investigator on numerous preclinical and clinical studies and has been involved in studies of many novel agents including implanted brain devices, optogenetic, homeoprotein, trophic factors GDNF, CNTF and dopamine lentiviral vectors.

Dr. Eberling earned undergraduate and graduate degrees in biological psychology from the University of California at Berkeley, later moving to the Lawrence Berkeley National Laboratory where she developed expertise in neuroimaging techniques and gene therapy approaches for Parkinsons disease.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http://www.axovant.com.

Contacts:

Investors

Parag MeswaniAxovant Gene Therapies Ltd.(212) 547-2523investors@axovant.com

Media

Josephine Belluardo, Ph.D.LifeSci Communications(646) 751-4361jo@lifescicomms.commedia@axovant.com

Go here to see the original:
Axovant Gene Therapies to Host Virtual Parkinson's Disease R&D Day on October 30, 2020 - BioSpace

Recommendation and review posted by Bethany Smith

CHAPEL HILL Babies born with a faulty maternal copy of the UBE3A gene will develop Angelman syndrome, a severe neurodevelopmental disorderwith no cure and limited treatments. Now, for the first time, scientists at the UNC School of Medicine show that gene editing and gene therapy techniques can be used to restore UBE3A in human neuron cultures and treat deficits in an animal model of Angelman syndrome.

This work, published inNatureand led by senior author Mark Zylka, PhD, Director of theUNC Neuroscience Centerand W.R. Kenan, Jr. Distinguished ProfessorofCell Biology and Physiology, lays important groundwork for a long-lasting treatment or cure for this debilitating disease, as well as a therapeutic path forward for other single-gene disorders.

Our study shows how multiple symptoms associated with Angelman syndrome could be treated with a CRISPR-Cas9 gene therapy, Zylka said.And we are now pursuing this with help of clinicians at UNC-Chapel Hill.

Left: UBE3A gene is off. Right: Using CRISPR, the gene is expressed and neurons fire (yellow). UNC images

Angelman syndrome iscaused by a deletion or mutation of the maternal copy of the gene that encodes the ubiquitin protein ligase E3A (UBE3A). The paternal copy ofUBE3Ais typically silenced in neurons, so the loss of maternalUBE3Aresults in a complete absence of the UBE3A enzyme in most areas of the brain. Thats crucial because the enzyme targets proteins for degradation, a process that maintains normal function of brain cells. When that process goes awry, the result is Angelman syndrome, a brain disorder with symptoms that include severeintellectual and developmental disabilities, seizures, and problems with speech, balance, movement, and sleep.

Turning on the paternal copy ofUBE3Ais an attractive therapeutic strategy because it could reverse the underlying molecular deficiency of the disease, Zylka said. However, the paternal gene is silenced by a long strand of RNA, produced in the antisense orientation toUBE3A,which blocks production of the enzyme from the paternal copy of the gene.

Members of the Zylka lab, including postdoctoral fellows Justin Wolter, PhD, and Giulia Fragola, PhD, set out to devise a way to use CRISPR-Cas9 to restore the UBE3A enzyme to normal levels by disrupting the antisense RNA. Preliminary data in cell cultures were promising, and Zylka received grants fromthe NIH, theAngelman Syndrome Foundation, and the Simons Foundation to test their findings in human neurons and in a mouse model of the disease.

In theNaturepaper, co-first authors Wolter and Hanqian Mao, PhD, a postdoc in the Zylka lab, and UNC colleagues describe using an adeno-associated virus (AAV) gene therapy to deliver the Cas9 protein throughout the brain of embryonic mice that model Angelman syndrome. Because UBE3A is essential for normal brain development, early treatment is crucial. The researchers found that embryonic and early postnatal treatment rescued physical and behavioral phenotypes that model core deficits found in Angelman syndrome patients. Remarkably, a single neonatal injection of AAV unsilenced paternalUbe3afor at least 17 months, and the data suggest this effect is likely to be permanent. The researchers also demonstrated that this approach was effective in human neurons in culture.

We were blown away when we got these results, Zylka said. No other treatments currently being pursued for Angelman syndrome last this long, nor do they treat as many symptoms. I am confident others will eventually recognize the advantages of detecting the mutation that causes Angelman syndrome prenatally and treating shortly thereafter.

Wolter added, The results of treating early were very promising. Since we learned we could reduce the severity of Angelman syndrome in mice, we are now focused on refining our approach in ways that will be suitable for use in humans.

While working to translate this research into the clinic, the Zylka lab will collaborate with researchers at the Carolina Institute for Developmental Disabilities (CIDD)to identify symptoms in babies that have the genetic mutation that causes Angelman syndrome.

Zylkas lab is working with CIDD researchers led by CIDD director Joseph Piven, MD, to use brain imaging and behavior observations to identify symptoms associated with Angelman syndrome in infants. Anecdotal reports suggest these infants have difficulty feeding and reduced muscle tone, but these and other early symptoms have not been rigorously characterized to date.

The idea is to use genetic tests to identify babies that are likely to develop Angelman syndrome, treat prenatally or around the time of birth, and then use these early symptoms as endpoints to evaluate efficacy in a clinical trial, Zylka said. Our data and that of other groups clearly indicate that prenatal treatment has the potential to prevent Angelman syndrome from fully developing.

As part of theNaturestudy, the researchers also found that the gene therapy vector blocked the antisense RNA by integrating into the genome at sites cut by CRISPR-Cas9. This so-called gene trap could be exploited to disrupt other long non-coding RNAs and genes.

Zylka added, We are incredibly excited to keep this work moving forward with the hope of helping children and families overcome this debilitating condition. Support from the NIH, the Simons Foundation, and the Angelman Syndrome Foundation was essential for moving this work forward.

Along with Zylka, Wolter, and Mao, co-authors of the Nature paper are Giulia Fragola, PhD, postdoc in the Zylka lab at the time of this research; Jeremy Simon, PhD, research associate professor; James Krantz, Zylka lab research associate; Hannah Bazick, Zylka lab graduate student; Baris Oztemiz, Zylka lab research technician; and Jason Stein, PhD, assistant professor of genetics and member of the UNC Neuroscience Center; all at UNC-Chapel Hill.

This research was funded by grants from the National Institutes of Health, the Simons Foundation, the Angelman Syndrome Foundation, the Eshelman Institute for Innovation, and the Pfizer-NCBiotech Distinguished Postdoctoral Fellowship in Gene Therapy.

(C) UNC-CH

See the rest here:
Gene editing shows promise as tool to fight neuro disorder in babies, UNC study finds - WRAL Tech Wire

Recommendation and review posted by Bethany Smith

A new research Titled Global Gene Therapy Market 2020 Research Report provides the Professional and In-depth evaluation of scope of current and future market and review of Product Specification, market trend , product type and production analysis considering major factors such as Facts and figure, revenue generated from the sales of this Report, market share and growth rate for each type and application, Gross Margin, key factors driving to the market. and also provides the In-depth evaluation of Gene Therapy Market using Porters five forces, SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the industry.

The Gene Therapy market will reach Volume Million USD in 2019 and CAGR xx% 2015-2019. The report Primarly enlists the basic details of industry based on the fundamental overview of Gene Therapy market chain structure, and describes industry surroundings, the development of the market through upstream & downstream, industry overall, investment analysis, manufacturing cost structure, industry policies, plans and development, key players will drive key business decisions and makes a scientific prediction for the development industry prospects on the basis of past, present and forecast data related to the Gene Therapy market from 2020-2024.

Request for Free Sample Report @:

https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#request_sample

Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

The Scope of the global Gene Therapy market mainly focuses on globally, it primarily covers the Gene Therapy Market in USA, Canada and Mexico, Gene Therapy Market in Germany, France, UK, Russia and Italy, global Gene Therapy market in China, Japan, Korea, India and Southeast Asia, global Gene Therapy market in Brazil, Argentina, Columbia, Global market in Saudi Arabia, UAE, Egypt, Nigeria and South Africa.

Gene Therapy Market Segmentation

Gene Therapy Market Segment by Type, covers:

Ex vivoIn Vivo

Gene Therapy Market Segment by Applications can be classified into:

CancerMonogenicInfectious diseaseCardiovascular diseaseOther

Get Best Discount on purchasing this report, Ask Here for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/130925

The firstly global Gene Therapy market describes the market overview, Upstream, Technology, Cost Structure. The second part describes global Gene Therapy market by key players, by Application and Type. It also includes Gene Therapy industry competition structure analysis by market revenue of region, sales and by Gene Therapy market by prominent key players. Also Consists of Global Gene Therapy Industry Application Status, Industry SWOT Analysis and Market Demand Forecast and analysis of Production and Sales of the regional market and future forecast analysis. Finally, it includes an analysis of Gene Therapy Market Investment, Market Features, Opportunity, and Calculation.

Enquire For Complete Sample Report Copy Or Request For Customization:

https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#inquiry_before_buying

Table of Contents:

Global Gene Therapy Market Size, Status and Forecast 2024

1 Industry Overview of Gene Therapy

2 Gene Therapy Competition Analysis by Players

3 Company (Top Players) Profiles

4 Global Gene Therapy Market Size by Type and Application (2015-2019)

5 United States Gene Therapy Development Status and Outlook

6 EU Gene Therapy Development Status and Outlook

7 Japan Gene Therapy Development Status and Outlook

8 Gene Therapy Manufacturing Cost Analysis

9 India Gene Therapy Development Status and Outlook

10 Southeast Asia Gene Therapy Development Status and Outlook

11 Market Forecast by Regions, Type and Application (2020-2024)

12 Gene Therapy Market Dynamics

12.1 Gene Therapy Industry News

12.2 Gene Therapy Industry Development Challenges

12.3 Gene Therapy Industry Development Opportunities (2020-2024)

13 Market Effect Factors Analysis

14 Global Gene Therapy Market Forecast (2020-2024)

15 Research Finding/Conclusion

16 Appendix

Explore Detailed Table Of Content With Table Of Figures: @

https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#table_of_contents

Read more:
Global Gene Therapy Market A Comprehensive Study Explores Huge Growth and Covers Updated Data Considering Post Impact of Covid-19 on Share, Size and...

Recommendation and review posted by Bethany Smith

Gene Therapy market report discusses the projections of the market covering the global scope and growth potential while providing detailed insights on various aspects essential for the growth of the market stakeholders and new players as well. This report has an evaluation of the Gene Therapy market over the period of 2020 through 2026. The report discusses in detail the all-inclusive landscape of the Gene Therapy Market.

Top Companies covering This Report: SangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVicalAdvantagene

The present Market scenario has been discussed and explained in detail in this report for the Gene Therapy market. The market size in terms of volume, share, revenue and growth size has also been discussed in a detailed assessment. The present situation as well as an account of the history of the Gene Therapy market is also explained in this research report.

NOTE: The report has been assessed in accordance with the COVID-19 Pandemic and its impact on the Gene Therapy market.

Get Sample PDF Brochure@ https://www.reportsintellect.com/sample-request/1413398?RINT

Description:

The research report provides detailed insights into the geographical regions covered under the Gene Therapy market. The report has been segmented and classified into various parts to give the client a more structured data profile to increase ease of use and efficiency. The report also has a classification of the Gene Therapy market on the basis of Types and Applications.

The report also profiles the major key players in the Gene Therapy market. With a comprehensive forecast account, the research report also has a detailed historic account on the Gene Therapy market landscape. The analysts have assessed this report in consideration with the top industry experts in the Gene Therapy market.

The Gene Therapy report highlights the Types as follows:Ex vivoIn vivo

The Gene Therapy report highlights the Applications as follows:Cancer DiseasesMonogenic DiseasesInfectious DiseasesCardiovascular DiseasesOthers

The report studies the following Geographical Regions:

Customization of the Report:

The given Gene Therapy market research report can also be customized as per the client requirements. The client can connect and get in touch with our sales team (sales@reportsintellect.com) who will ensure that you get the report as per your requirements and needs.

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/1413398?RINT

Some Key Questions answered in this Report are:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.comPhone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Gene Therapy Atlanta, GA 30303

See the rest here:
Gene Therapy Market : 2020 Based on Comprehensive Future Insights and Technological Advancement by 2026 - Stock Market Vista

Recommendation and review posted by Bethany Smith

PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people dont respond at all. KSQ Therapeutics hopes to provide hope for those patients with a first-in-class drug that may be able to boost Lynparzas effectiveness when used in combination with itand the company has rolled out promising animal data to back up that strategy.

KSQs drug inhibits ubiquitin specific peptidase 1, an enzyme that has been shown to promote the survival of cancer cells by facilitating DNA repair. The drug, dubbed KSQ-4279, inhibited tumor growth both on its own and when combined with Lynparza in mouse models of ovarian and triple-negative breast cancers, the company reported during a presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

KSQ discovered the drug using a technology platform it calls CRISPRomics, which allows its researchers to identify therapeutic targets by applying CRISPR-Cas9 gene editing to the whole genome. The company has used the platform to study 20,000 human genes in 600 cancer models.

RELATED: KSQ grabs $80M to move T-cell treatment for PD-1 resistance into the clinic

PARP inhibitors work by interrupting DNA repair, but KSQs researchers believe KSQ-4279 inhibits different yet complementary DNA repair pathways, said the companys chief scientific officer, Frank Stegmeier, Ph.D., in a statement.

In multiple animal models of ovarian cancer and triple-negative breast cancer, combining KSQ-4279 with Lynparza was more effective than either drug on its own. The combo approach prompted a complete response in some of the breast cancer models.

PARP inhibitor combinations are gaining steam in the oncology market. In May, the FDA approved a combination of Lynparza with Roches VEGF inhibitor Avastin to treat ovarian cancer with or without BRCA mutations.

Last year, Yale University researchers discovered that AstraZenecas experimental VEGF inhibitor cediranib also prevents DNA repair. The researchers suggested that cediranib could make tumors more responsive to Lynparza and other PARP inhibitors.

As for KSQ, it has grown quickly over the last few years, raising $76 million in 2017 and another $80 million a year later to advance its lead programs, one of which is a T-cell therapy for solid tumors that are resistant to PD-1 immune checkpoint inhibitors. KSQ-4279 is now its lead program, and the new data in ovarian and breast cancers give the company confidence to advance the drug into clinical trials as a novel agent in a new class of targeted oncology treatment, Stegmeier said.

See the original post here:
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor - FierceBiotech

Recommendation and review posted by Bethany Smith

Stem Cell-Derived Cells Market report 2018, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Stem Cell-Derived Cells Market research Reports offers an extensive collection of reports on different markets covering crucial details. The report studies the competitive environment of the Stem Cell-Derived Cells Market is based on company profiles and their efforts on increasing product value and production.

This Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

The report analyzes the market of Stem Cell-Derived Cells by main manufactures and geographic regions. The report includes Stem Cell-Derived Cells definitions, classifications, applications, and industry chain structure, development trends, competitive landscape analysis, and key regions development and market status.

By Market Players:

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Reasons to Purchase This Report:

Market analysis for the global Stem Cell-Derived Cells Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the market with the help of Porters five forces analysis

Which textile, raw material, and application is expected to dominate the market

Which country is expected to witness the fastest growth during the forecast period?

Identify the latest developments, market shares and strategies employed by the major market players.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

The key insights of the Stem Cell-Derived Cells market report:

Visit link:
Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire

Recommendation and review posted by Bethany Smith

RenovaCare Commences Investor Presentations

RenovaCare Commences Investor Presentations; Webcast on October 29, 2020 at 11:00 AM EDT

ROSELAND, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; http://www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will begin presenting business and financial updates, with the first scheduled for October 29, 2020 at 11:00 a.m. (EDT), to be held via online webcast.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ab4ca73-7a9f-44f3-93f7-c2dd50571f3a

During the webcast, RenovaCare management will provide an overview of the Companys performance in 2020 year-to-date and also discuss its business objectives for 2021.

Interested investors, analysts and media representatives are invited to participate in the webcast via the following link:

Link to Register for RenovaCare Oct. 29, 2020 Investor Presentationhttps://edge.media-server.com/mmc/go/RenovaCare10292020

As investor engagement is important to RenovaCare, all interested parties will have the opportunity to ask questions by submitting them to investor_relations@renovacareinc.comby 3:30 p.m. eastern daylight time on October 28, 2020. Shareholders will also have the ability to ask questions during and following the presentation through a chat box with the presentation operator.

The webcast will be recorded and available for playback after the meeting through the RenovaCare website atwww.renovacareinc.com.

RenovaCarepatented investigative technologies are currently in development. They are not available for sale in the United States or elsewhere. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration or other regulatory authorities will be accepted or cleared.

About RenovaCareRenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the bodys largest organ, the skin. The companys flagship technology, the CellMist System, uses its patented SkinGun to spray a liquid suspension of a patients stem cells the CellMist Solution onto wounds.

Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Companys SkinGun, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

For additional information, please call Amit Singh at: 888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit:https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/Follow us on Twitter:https://twitter.com/RenovaCareIncFollow us on Facebook:https://www.facebook.com/renovacarercar

Social Media DisclaimerInvestors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking StatementsNo statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Continue reading here:
RenovaCare to Commence Investor Business and Financial Presentations; Webcast on October 29, 2020 - GlobeNewswire

Recommendation and review posted by Bethany Smith

Augustinus Bader on his revolutionary approach to skincare

The mind behind the most coveted products in beauty discusses thescience behind the brand

When Augustinus Bader first launched The Cream in 2018, it was hailed as a miracle. In a matter of weeks, it could transform any skin type within any age range, dispelling wrinkles, redness, dryness, scaring, visible pores, sagginess, and practically every other skin concern it would usually take a shelf load of serums to combat. While miraculous, magical, and other mystical attributions caneasily, and quite fairly, be applied to Augustinus Bader products, the real genius of the brand comes down to pure science.

The Augustinus Bader skincarebrand was the by-product of its namesakes development of medical-grade cream, which could heal severe burn injuries to an extent that was previously only possible through skin grafts. Professor Bader, a stem cell and biomedical scientist at Leipzig University, was hoping to get the cream backed by a pharmaceutical company but, in the words of his business partner Charles Rosier, clinical trials cost tens of tens of millions of dollarsand the majority of accidents around burns happen to children, often in third-world countries. For a pharmaceutical company, when the outcome is not necessarily the most profitable outcome, theres less interest.

Inspired to make Baders cream widely available, Rosier encouraged the Professor to translate the principles of his burn cream into skincare. In my mind, I thought, if we create a cream thats superior to whats on the market and its a big success, then he can focus on is research and we can finance the clinical trial.

Baders cream centred around one, revolutionary hypothesisthat the body already possesses all of the stem cells it needs to regenerate itself. The problem, when it comes to the skins inability to heal from severe injuries or just the everyday effects of ageing, is that the bodys ability to trigger those regenerative cells has been impeded.

Bader developed this hypothesis based on two observations. First, that the size of the wound affects the bodys ability to heal. Asmall paper cut heals quickly, while a large scale burn takes time to heal and often leaves scar tissue. Secondly, the body automatically knows where the site of an injury is. When you cut your left hand, your body immediately starts sending cells to the area of the cut so that the skin can rebuild. Yet,the same tissue would never rebuild on your right hand because it rebuilt on your left. Only where there is a wound is the body rebuilding.

In Baders words, If the cut is super small, you would have a small distance between the edges of the cut skin and the cells can still communicate over this small distances through the hand, and would close the wound. But if you burn your hand, the cells would be dying and the signal response cannot arrive at this injury. The response is totally different, the small cut heals perfectly, while on the other side the big injury kills this confirmation.

So the basis of [my] hypothesis is that this is probably just the absence of specific molecules that cannot arrive to the site of the injury because cells are dying or are blocked. So many, many years ago I started trying to find solutions to this problem because genetically speaking were the same human being, why would we have these limitations, why would we have these problems? It doesnt make any sense.

I thought, why not try to replace what the cells would be doing if they were present? That triggering complex, which singles the cells to respond to the injury, or, when it comes to skincarewrinkles, is the secret, miracle likeelement of Baders cream.

Unlike most skincare, which just changes the outside surface of the skin, Baders skincare works from the inside out, transforming the bodys internal, cellular communication for exterior changes. I think ageing is just a lack of repair, a lack of regeneration. Skin is a living organism, which has to be remodelled, meaning repaired a little bit everyday. But you can accelerate this repair lead.

Theres something super, super sensitive inside of you, which are these cells that sense the microenvironment and respond to the need. So the cream, in a way, is only a toolbox, which helps your stem cells when they sense this need to interact more appropriately.

This new approach to the effects of ageing is a revolution in skincare that, no doubt, heralds the beginning of a new science-driven, cellular-focused trend in the industry.

This year, Bader has launched a number of additional products to his line beyond The Cream and its companion The Rich Cream. The new additions include a Cleansing Gel, Face Oil, Body Cream and, as of today, Cleansing Balm with more releases set for the next year.

Visit link:
Augustinus Bader on his revolutionary approach to skincare - Wallpaper*

Recommendation and review posted by Bethany Smith

Getting up there in years comes with its drawbacks and benefits, and the onset of facial lines and volume loss that comes tends to top the list of drawbacks. You can count facial aging right up there with the onslaught of back pain and the occasional grey hair turning into a full head of silver. To soften those where did they come from facial lines and give skin a more youthful glow, these anti-agers target the main offenders: wrinkles and uneven skin tone and texture.

2/8

Glycolipids in Dr. Loretta Intense Replenishing Serum ($70) trash moisture on the skin surface to help hydrate skin while the antioxidant lipochroman combats free radicals and protects from harmful UV light, leaving skin looking plump, smooth and rejuvenated.

3/8

Apply a layer of Augustinus Bader The Face Oil ($230) morning and night. Utilizing Professor Baders TFC8 technology, the oil promotes cellular renewal, which helps smooth skin texture and reduce the look of fine lines and wrinkles.

4/8

The name says it all with ZO Skin Healths Firming Serum ($235). Lightweight and tolerable for even sensitive skin types, this anti-ager includes the brands ZCORE complex which consists of a synthetic tetrapeptideand sweet yellow clover to help strengthen skin laxity. Plant stem cells provide powerful antioxidant protection while sodium DNA helps stimulate cell repair and reduce inflammation.

5/8

Harnessing the brands signature ingredient, La Prairies Skin Caviar Liquid Lift ($690) blends two types of caviar, Premiere and Absolute, into a milky emulsion to deliver the perfect dose of serum that promises firmer skin and enhanced elasticity.

6/8

Bioeffect Limited Edition EGF Serum ($495) is said to have twice the original EGF formulas anti-aging benefits due to its inclusion of a rare black barley that is grown at the brands state-of-the-art greenhouse in Iceland. The EGF stands for Epidermal Growth Factor, which in this serum is totally plant derived and signals skin cells to prompt collagen and elastin production. The unique black obsidian bottle design was created by Icelandic artist Shoplifter.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read more:
8 Skin-Boosting, Anti-Aging Treatments for Generation Xers and Beyond - NewBeauty Magazine

Recommendation and review posted by Bethany Smith

Top notch ingredients are vital when it comes to creams. We chatted with skin care pros to see which ingredients are the best . This helped us pick out the products with the most oomph.

We also factored in:

Pricing guide

Night creams def have a rep for being expensive and some totally are. You should expect to pay more for extra bells and whistles (e.g. designer brands, fancy packaging, etc.). But thats definitely not the case percent of the time. You can find awesome, dermatologist-recommended products for around $10.

This guide will help you pick the best cream for your skin and budget:

$ = $10$20$$ = $25$50$$$ = $51$75$$$$ = over $76

Whether youre looking for a simple cream that gives your skin a glowy boost or a powerful cream for more mature skin to help reduce fine lines, theres a cream for you. Here are the top 22 night creams for every need.

Price: $$$$

Designed for all skin types, this lightweight cream uses retinol to reduce the appearance of lines. Hyaluronic acid delivers hydration and improves skins tone and texture. It also has niacinamides and picolinamides that support your skins natural barrier and lock in moisture.

Cons: Some peeps with sensitive skin said it caused irritation.

Buy Murad Retinol Youth Renewal Night Cream online.

Price: $

Unlike some heavy duty hydrators, this cream is oil-free and wont clog pores. You can use it day and night without worrying about pesky pimples.

It has the benefits of anti-aging while being lightweight enough to not trigger acne, says dermatologist Erum Ilyas, MD, MBE, FAAD. If youre looking for a cream but dont want to risk breakouts, this is a nice one to try.

Cons: It might not be hydrating enough for dry skin.

Buy OLAY Total Effects 7-in-1 Anti-Aging Moisturizer online.

Price: $$

Found: An overnighter that fights the signs of aging and keeps breakouts at bay. Retinol helps plump skin to reduce the appearance of lines and wrinkles. Salicylic and lactic acids keep bacteria from clogging pores and causing breakouts.

Cons: Salicylic acid can be drying.

Buy Arcona PM Blemish Lotion online.

Price: $$

This concentrated balm harnesses the power of colloidal oatmeal and sweet almond oil to soothe itchy, inflamed skin. It promotes a smoother and more even skin texture and can help reduce redness. Its even safe to use around your eyes and on your lids.

Cons: Some users found the rich texture to be a bit greasy.

Buy Skinfix Eczema Dermatitis Face Balm online.

Price: $$

This cream delivers heavy duty hydration to fight ashiness (thanks, avocado and shea butter). The vitamin C can help combat hyperpigmentation from exposure to UV rays (which is more likely in darker skin).

Cons: It might trigger breakouts in oily or acne-prone skin.

Buy Eve Hansen Vitamin C Night Cream online.

Price: $$

This super hydrating treatment straddles the line between cream and mask. Ingredients like squalene, glycerin, and fountain plant quench parched skin. It also helps protect the skins natural barrier to keep moisture in.

Cons: Some users complain that the texture is too thick to the point of being straight up sticky.

Buy Kiehls Ultra Facial Overnight Hydrating Masque online.

Price: $$$$

Dermatologist Deborah Longwill, DO, FAOCD, counts this potent potion as a current fave.

It combines the anti-aging ingredient resveratrol with antioxidant-rich ingredients like glycoin and ectoin, she explains.

These ingredients help shield your skin from environmental stresses. They also work to enhance elasticity, improve texture, and hydrate cells.

Cons: Its on the spendy side.

Buy Doctors Daughter Extremolyte Stem Cell Serum online.

Price: $$$

This hydrating-but-not-overly-heavy cream nourishes and plumps skin with ingredients like ceramides and hyaluronic acid. Oh, and its been clinically tested to reduce fine lines, dryness, and loss of firmness in just 7 nights.

Cons: Steer clear if youre not a lavender fan.

Buy IT Cosmetics Confidence in Your Beauty Sleep Night Cream online.

Price: $$

Does added fragrance irritate your skin? Same. Thankfully, this non-irritating cream that gets the job done. Its also loaded with vitamin E which fights redness and inflammation.

Cons: This cream is definitely on the thick side. It might feel heavy on oily skin.

Buy Olay Regenerist Night Recovery Anti-Aging Face Moisturizer online.

Price: $

Retinols a go-to ingredient for minimizing the appearance of fine lines thanks to its ability to protect the skin-plumping protein collagen.

It also has hyaluronic acid, a moisturizer to help prevent irritation and dryness that may be a better option for those with dry or sensitive skin, says dermatologist Susan A. Bard, MD.

Cons: Some users report experiencing redness or rashes.

Buy Neutrogena Rapid Wrinkle Repair Night Moisturizer online.

Price: $$$

This cream uses bakuchiol, a natural retinol alternative. Thats good news if you have sensitive skin.

Its a functional analog of retinol meaning it has the same effect, with one huge advantage: Its less irritating because its also an anti-inflammatory agent, Ilyas says.

Cons: Its got a strong peachy scent that you might love or hate.

Buy OLEHENRIKSEN Goodnight Glow Retin-Alt Sleeping Crme online.

Price: $

Ahhh. Heres a cooling gel cream made with licochalcone, a licorice-based skin soother. It fights redness and irritation in folks with sensitive, rosacea-prone skin. The creams noncomedogenic so it wont clog your pores either.

Cons: This stuffs very gentle. But it still might be too strong on super sensitive skin. Def do a patch test before slathering it all over your face.

Buy Eucerin Redness Relief Night Cream online.

Price: $

Bard loves recommending this simple, no-frills wrinkle fighter to patients. Its inexpensive, easy to find at most drugstores, and it works.

It contains retinol which helps improve fine lines and wrinkles, stimulate collagen production and decrease pigmented spots, she says.

Cons: The retinol in this formula is designed for daily use. But its still worth starting off gradually and work your way up. This gives your skin time to adjust.

Buy RoC Retinol Correxion Deep Wrinkle Night Cream online.

Price: $$

Lotus and peach extract fight oxidative stress and keep your skin looking glowy. But what really sets this lightweight cream apart is the floral peach aroma that comes wafting out the second you open the jar. Another perk: Its good for all skin types.

Cons: Its not formulated to fight fine lines or wrinkles.

Buy Lotus Youth Preserve Dream Face Cream online.

Price: $$$

Grease is not the word here. The gel formula delivers hydration but its still light and cooling. Its got niacinamide, viniferine, and natural pearlizers to fight the appearance of dark spots even out skin tone.

Cons: Some peeps said it didnt brighten their skin.

Buy Caudalie Vinoperfect Instant Brightening Moisturizer online.

Price: $$$

TBH the whole women vs. men products thing is silly. Right? But this cream feels a bit more manly thanks to the neutral packaging and woodsy scent. It fights fine lines and wrinkles with retinol and uses the antioxidant ferulic acid to combat dark spots and sun damage.

Cons: The heavy-duty retinol can be a little harsh especially if your skins not used to it.

Buy Dr. Dennis Gross Ferulic + Retinol Moisturizer online.

Price: $$

Glycolic acid is great at reducing the appearance of dark spots because it can suppress the production of melanin. The acid improves skins elasticity and boosts firmness too. So its an all-around awesome fountain of youth-kinda option.

Cons: Its a serum. If youre looking for hydration, youll still want to layer a moisturizer over top.

Buy Bolden Nighttime Repair Serum with 10% Glycolic Acid online.

Price: $$

Vitamin C and collagen are your eyes BFF. They brighten and plump the delicate skin around your peepers. This ones got both and a little goes a long way.

Cons: Its thick and rich. So it might clog your pores if it ends up on your T-zone.

Buy OLEHENRIKSEN Banana Bright Eye Cream online.

Price: $$$

This certified-organic cream boasts vitamin C, fruit stem cells, grape-seed oil, and squalene. It will brighten and hydrate without the use of parabens, petroleum, sulfates, pesticides, or phthalates.

Cons: The grape-seed oil might be too much for oily or acne-prone skin.

Buy Juice Beauty Stem Cellular Anti-Wrinkle Overnight Cream online.

Price: $

You can legit get amazing results from a night cream without spending megabucks. This dermatologist-developed moisturizer plumps and renews skis with a peptide complex. It also restores the skins natural barrier with essential ceramides. Plus its not greasy!

Cons: This is definitely a utilitarian option. If you love extras like scents or pretty packaging, skip it.

Buy CeraVe Skin Renewing Night Cream online.

Price: $

The suns UV rays can seriously stress your skin. This can cause dark spots, discoloration, and fine lines. But ingredients like green tea and vitamin C help fight sun-induced stress. This hydrating cream delivers both.

Cons: The packaging looks like it came from 1995, which, depending on what youre going for might ruin your #shelfie. (Or maybe not.)

Buy LILY SADO TEA+C Green Tea + Vitamin C Moisturizer online.

Price: $

Snow mushroom and sodium hyaluronate deliver mega moisture, while soothing lavender oil and chamomile extract help you chill and unwind. After anointing yourself with this vegan lotion, you might just wanna close your eyes and doze off.

Cons: You wont get as much anti-aging action here.

Original post:
22 Best Night Creams 2020 for All Skin Types and Concerns - Greatist

Recommendation and review posted by Bethany Smith

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

Fashion, beauty, health and wellness are all intertwined. You cant really have one without the other

The Clinique La Prairie (CLP) in Montreux, Switzerland has been purveyors of luxury health and wellness for 89 years. This is Switzerlands thing, and one of the main reasons why people travel to the scenic nation of wellness facilities, mountains and natural springs because the country knows and understands the value of health and wellness, especially in this time of Covid. There are facilities like CLP all over Switzerland, with expert and advanced care that offer an intimate luxury environment. For CLP, its their mission to partner with visitors by providing personalized treatment to help and inspire people to live longer, healthier and better lives.

Our vision is always looking at pioneering longevity, says Simone Gibertoni, the CEO of CLP. As the future of wellness is linked to epigenetics, genomics, mental wellness and many more inspiring sciences, we are also taking a particular interest in research on microbiota, senescent cells and their markers, stress and sleep, circadian rhythms- among other aspects of life science and biology, in an effort to determine how they can be used to promote holistic longevity. This approach is envogue and the most fashionable lifestyle implementation that an individual can make in an effort to promote self-longevity.

So, how has this facility overlooking Lake Geneva been able to carry on a mission and vision of world class wellness- with the aim of opening up CLP facilities in Bangkok and Madrid this year, and, other facilities throughout the Middle East, Asia and the Americas in the future? From its inception in 1931 by Professor Paul Niehans, who pioneered development cell therapy, CLP almost ninety years later has continued to expand due to top health and wellness innovations. With fifty specialists, wellness programs that range from immune-boosting and anti-aging revitalization, and luxury hospitality all combined in a state-of-the-art facility, the clinic has been able to grow after all this time and keep people living longer in the process.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

We believe that health is not only the absence of illness, but the balance of mind, spirit and body, continues Gibertoni.Our guests have the privilege of being accompanied and advised in the ultimate refinement, and benefit from the expertise of leading specialists, from renowned doctors to experts in sport, wellness, and nutrition.

Pioneering health and wellness in the age of covid

As CLP is leading in immunity, they know this is on everyones mind this year, and they are seeing a demand of people wanting revitalization programs, a type of holistic offering that boosts the immune system, while upgrading the mind and body notes Gibertoni. In response to COVID-19, we have introduced new elements to it, including immuno-fortifying ingredients, enhanced nutrition coaching and wellness solutions to help activate the immune function, Gibertoni says. In its one-week approach, Revitalization helps to combat stress and infections and to improve health related setbacks. The Revitalization has been carried out exclusively at CLP for nearly nine decades and does include the CLP Extract, containing biologically active substances, given in conjunction with bio-stimulants.

Recognizing that todays lifestyle can attack the immune system, CLPs MASTER DETOX program provide solutions. Stress, food treated with pesticides, overconsumption and demanding situations like the current one exposes us to a vast quantity of toxins which affect our bodies regeneration capabilities, which can lead to fatigue, digestive problems, allergies or a weakened immune system, says Gibertoni. And in the age of Covid, these negative factors are a need for the body to be eliminated of toxins and promote physiological balance. In this new MASTER DETOX week, we focus on a Cellular Genomic detoxification protocol, in line with our scientific approach, and as always on individual plans based on the four pillars of medical, nutrition, wellbeing and movement.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers one-on-one services about the state ... [+] and health of your body and how to increase longevity.

Fashion and beauty start with wellbeing

Gibertoni gives a fitting example of how beauty is birthed out of a good wellbeing regiment.

The first: every health and wellbeing program is also about revealing beauty, because each creates a bespoke path to feel good inside and out. What you eat, your level of stress, your lifestyle habits, your sleep quality, your possible vitamins deficiencies, ... these are all factors very directly impacting beauty.

For example, nutrition based on antioxidants and nutrients that help reduce internal inflammation will support protection against free radical effects and promote hydration. Through individual consultations about longevity, DNA insights, nutrition and movement, and of course body and skin advanced treatments, many factors are addressed in a holistic way during the week program that the guest spends at CLP, leading to help restore healthy foundations and routines, and ultimately boosting radiance.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers holistic treatments like massages.

For CLP, revitalization and their MASTER DETOX program has been tried and tested against a radical anti-aging and medical science, so their programs have been able to stand the test of time with their treatments, technologies and coaching that amplify a persons wellbeing.

The most top fashion model, designer, and fashion connoisseur cant have a successful run at fashion without a proper health and wellness regimen, and an occasional visit to a clinic like CLP if they can afford it.

The second dimension is about CLPs cutting-edge programs that focus specifically on anti-aging and regenerative medicine, with an integrative approach to rejuvenation. We help realize the personal journey to look, feel and live well, with cutting edge anti-aging aesthetics protocols for men and women, where all aspects of the body and face are taken into consideration.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

They do this through stem cell-based programs of the likes of their Beauty Stem Cells and Cell Boast Facelift, where an individuals own stem cells are clinically harvested and re-injected and they also revitalize the skin using natural resources from ones own body to regenerate and slow down aging. All of this results in restoring a persons youthful appearance. Non-invasive aesthetic medicine delivers the latest solutions in the advancing field of preventive and restorative aesthetics. And their 4-5-day beauty holistic programs utilize a holistic approach to beauty by using non-invasive technologies from CLPs anti-aging research.

We all know the latest runway collections are envogue and we all want to look fashionable and have our beauty top notch. What we do for our bodies, from what we put into it and how we treat it will result in our beauty and make us illuminate our various and unique fashion styles. CLP gets people there by going deeper and under the surface by identifying nutritional and lifestyle changes that their visitors need to implement into their lives. All of this leaves people looking radiant, sculpted, balanced and more youthful by the time they leave our facility, as Gibertoni points out and it provides long-lasting effects.

Find out more about Clinique La Prairie in Montreaux and stay tuned for their upcoming new location openings- here.

Read more:
How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes

Recommendation and review posted by Bethany Smith